This study aims to assess the efficacy of the HALP-H index, which combines the HALP score and the H index, in forecasting pathological response to neoadjuvant treatment in HER2-positive early and locally advanced-stage breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.